Estimates of HPV Vaccine Prevention of HPV-Associated Cancers …MOM AND DAD TAKE NOTE AND VACCINATE YOUR KIDS
- The HPV-16/18 vaccine was estimated to prevent the majority of invasive cervical, anal, oropharyngeal, and vaginal cancers.
- The nine-valent vaccine was estimated to prevent an additional 5.7% to 18.3% of cancers.
A study by Saraiya et al reported in the Journal of the National Cancer Institute investigated the prevaccine prevalence of human papillomavirus (HPV) by HPV-associated cancer category and estimated the proportion of cancers prevented by vaccine targeting HPV-16/18 and by the nine-valent HPV vaccine.
In the study, the Centers for Disease Control and Prevention obtained archival tissue for cancers diagnosed from 1993 to 2005 from seven U.S. population–based cancer registries and performed HPV testing on 2,670 case patients who were representative of participating registry cases by age and sex. Current U.S. cancer registry data and detection of HPV types were used to estimate the number of cancers potentially preventable by HPV vaccination.
Overall, HPV DNA was detected in 90.6% of cervical (98.8% of cervical cancer in situ), 91.1% of anal, 75.0% of vaginal, 70.1% of oropharyngeal, 68.8% of vulvar, 63.3% of penile, 32.0% of oral cavity, and 20.9% of laryngeal cancers.
Vaccine targeting HPV-16/18 was estimated to potentially prevent 24,858 cancers annually, including 66.2% of invasive cervical, 79.4% of anal, 60.2% of oropharyngeal, 55.1% of vaginal, 47.9% of penile, and 48.6% of vulvar cancers. The nine-valent vaccine (also targeting HPV-31, 33, 45, 52, and 58) was estimated to prevent an additional 3,944 cancers annually, including an additional 14.7% of invasive cervical, 8.2% of anal, 5.7% of oropharyngeal, 18.3% of vaginal, 9.0% of penile, and 14.2% of vulvar cancers.
The investigators concluded: “In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new [nine-valent] vaccine.”
Mona Saraiya, MD, MPH, of the Centers for Disease Control and Prevention, is the corresponding author of the Journal of the National Cancer Institute article.
The study was supported by the Centers for Disease Control and Prevention.